DaVita Inc. stock performance trend indicates that the stock price has rallied 3.99% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 2.62% . Looking at the past 52 week period, the stock price is down -6.79% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of DaVita Inc. has a negative value of -13.74 compared to overall market performance.DaVita Inc. is having a Relative Strength Index of 51.17 which indicates the stock is not yet over sold or over bought based on the technical indicators.
DaVita Inc. (NYSE:DVA) has tumbled 1.09% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 1.35% in the last four weeks. The stocks have underperformed the S&P 500 by 1.33% during the past week but DaVita Inc. (NYSE:DVA) it has outperformed the index in 4 weeks by 0.19%.
Company shares have received an average consensus rating of Hold for the current week DaVita Inc. (NYSE:DVA) : On Friday heightened volatility was witnessed in DaVita Inc. (NYSE:DVA) which led to swings in the share price. The stock opened for trading at $67.73 and hit $67.87 on the upside , eventually ending the session at $67.8, with a gain of 0.09% or 0.06 points. The heightened volatility saw the trading volume jump to 1,721,465 shares. The 52-week high of the share price is $78.77 and the company has a market cap of $13,194 million. The 52-week low of the share price is at $54.5 .
Company has reported several Insider transactions to the SEC, on Feb 27, 2017, Leanne M Zumwalt (Grp VP, Purch & Public Affairs) sold 807 shares at 68.72 per share price.On Aug 11, 2016, Michael David Staffieri (COO, Kidney Care) sold 20,262 shares at 73.09 per share price.On Jul 13, 2016, Jeanine Marie Jiganti (Chief Compliance Officer) sold 1,291 shares at 78.51 per share price.
DaVita HealthCare Partners Inc Last issued its quarterly earnings results on Feb 16, 2017. The company reported $0.98 EPS for the quarter, beating the analyst consensus estimate by $ 0.07. Analyst had a consensus of $0.91. The company had revenue of $3715.70 million for the quarter, compared to analysts expectations of $3740.69 million. The companys revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.
DaVita Inc. is the parent company of DaVita Kidney Care and HealthCare Partners. DaVita Kidney Care is a provider of kidney care, delivering dialysis services for chronic kidney failure and end stage renal disease primarily in the United States. HealthCare Partners manages and operates medical groups and affiliated physician networks primarily in California, Nevada, New Mexico, Florida, Colorado and Washington. DaVita Inc., formerly known as DaVita HealthCare Partners Inc., is headquartered in Denver, Colorado.